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UPDATE ON OSTEONECROSIS RELATED TO
BISPHOSPHONATES: A REPORT OF THREE CLINICAL
CASES
Edgard Nehmé* | Nadim Khoueir** | Jeanine Hoyek-Gebeily***
Abstract
The publications issued since 2003 on osteonecrosis related to oral and / or iv bisphosphonates (BsP) lend a controversy. The recommendations and guidelines from senior scientific authorities reviewed and updated in 2009 by the task force of the AAOMS, define
patients in terms of risk and determine practically the prophylactic acts and the limits of operative oral and dental procedures. In
these serial clinical cases, we report and discuss three situations with different therapeutic approaches and management.
Keywords: bisphosphonates – osteonecrosis- hypercalcemia.
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MISE À JOUR SUR L’OSTEONECROSE LIÉEAUX BISPHOSPHONATS:
A PROPOS DE TROIS CAS CLINIQUES
Résumé
Les publications parues depuis 2003 sur les ostéonécroses liées aux prescriptions des bisphosphonates (BsP) oraux et/ou par voie
intraveineuse prêtent à des controverses. Les recommandations émanant de hautes autorités scientifiques, revues et mises à jour
en 2009 par l’AAOMS, définissent mieux les patients en termes de risque et déterminent de façon pratique les mesures prophylactiques et les limites des actes opératoires oraux et dentaires. Dans cette série de cas cliniques, nous rapportons, discussion à
l’appui, trois situations et approches thérapeutiques différentes.
Mots- clés : bisphosphonates – ostéonécrose- hypercalcémie.
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Introduction
Bisphosphonates (BsP), known for
inhibiting osteoclast’s activity, have
been used for the treatment of osteoporosis since 1960s. They’ve been also
implicated in the treatment of hypercalcemia and metastatic cancers. In
2003, Marx [1] reported the first cases
of BRONJ (Bisphosphonates-Related
Osteonecrosis of the Jaws). In 2007,
the American Association of Oral
and Maxillofacial Surgeons (AAOMS)
adopted in the position paper the case
definition on BRONJ based on three
main characteristics: current or previous treatment with a BsP, exposed
bone in the maxillofacial region for

more than eight weeks and no history
of radiation therapy in the jaws [2]. In
2006, Woo et al. [3] reviewed 368 cases
revealed some main aspects of BRONJ:
most of them (94%) were associated
with the intra-venous form and in the
treatment of cancer-related hypercalcemia (86%). Moreover, the mandible was
the most affected site (65%) and more
cases were described in women (sex
ratio 3:2).
Numerous risk factors have been
associated with BRONJ: potency of the
drug, the intra-venous form, treatment
duration, cancer, periodontal disease,
dento-alveolar surgery, local anatomy

(tori, exostosis), age over 65 years and
genetics [4]. Other factors have also
been described like corticotherapy,
head and neck radiotherapy, chemotherapy, anemia, smoking, coagulopathy, anemia and diabetes (Robertsona
et al., [5]).
Bone turnover can be evaluated
using a test that measures carboxyterminal collagen crosslinks (CTx) in
serum. With this test, clinicians can
assess the risk of developing BRONJ
(CTx < 100 pg/ml ↔ high risk; CTx =
100- 150 pg/ml ↔ moderate risk; CTx
> 150 pg/m ↔ minimal risk) (Marx et
al., [6]). However this test has not been
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independently validated and its use
for estimating the risk of BRONJ is still
controversial.
The true incidence of BRONJ is still
unknown with wide variations among
studies. Indeed, based on case-series,
case-controlled and cohort studies,
estimates of the cumulative incidence
of BRONJ in case of iv route of administration range from 0.8%-12% (Marx et
al., [6]). However, the incidence is much
lower in the oral form series. For example, the incidence calculated by Merck
with alendronate was 0.7/100,000 person/years of exposure [7]. Highest rates
were reported in an Australian study
(Ault, [8]) (0.01% to 0.04% with spontaneous occurrence and 0.09% to 0.34%
after extractions). Finally the incidence
estimated by Sedghizadeh [9] with the
oral forms was as high as 4%.

Fig. 3: Panoramic film.

Fig. 1: Osteonecrosis at tooth #16.

Case 1
A 70-year old male presented in
October 2008 with acute pain and
open wound at the site of tooth #16
that was extracted 2 months ago. Upon
examination, some degree of advanced
bone necrosis was revealed (Fig.1). The
patient had a history of a right renal
adenocarcinoma with bone metastasis treated in 2006 with right nephrectomy, chemotherapy (Proleukine for
6 months) and total dose radiotherapy. His current medication included
Sutent® (sunitimib, 50mg) and iv
Zometa® (zoledronic acid, 15 mg every
2 weeks for 3 months; then 2mg every 4
weeks; then 1 mg every 4 weeks for 21
months). He was still complaining of
back and hip pain. A bone scintigraphy
done in May 2008 showed hyperfixation
at vertebral levels (D9, L2, and L3), right
iliac bone, bilateral humerus, proximal
right femur and right maxillary sinus
suggesting either a metastatic focus or
an evidence of a chronic inflammatory
disease (Fig.2).
A panoramic film was then taken;
it showed a poorly-defined image of
crestal maxillary bone loss around the
lesion described above with no radiographic evidence of oral-sinus communication (Fig.3). A sinus CT scan also

Fig. 2: Bone scintigraphy after iv injection of 19 mCi of HMDP-Tc.

revealed a condensation of the right
maxillary sinus (Fig.4). The patient was
subsequently admitted to the hospital
for bone curettage extending to the
right maxillary sinus wall (Fig.5). The
purpose was to determine the histological nature of the hyperfixation image
(inflammatory or metastatic origin).
The histo-pathological exam showed
signs of osteonecrosis and chronic
sinusitis without evidence of malignancy. Thus, he was treated with iv
antibiotics (amoxicillin + clavulanate)
and Zometa® was stopped. The patient
was discharged under oral antibiotics
(amoxicillin + clavulanate) for 2 weeks
and a stent (obturator) was placed a
few days afterward.
A follow-up visit in May 2009
showed intense necrotic bone loss in

distal tooth #15 and a bone regularization was then conducted (Fig.6). In
October 2009, the patient presented
with an acute peri-mandibular cellulitis extending from tooth #36. He
was treated with 4 weeks oral antibiotics (amoxicillin+clavulanate) and
Bétadine® oral rinse. One week later,
teeth #15 and #36 were extracted
because of terminal bone loss with pain
and mobility. Bone regularization was
done (Fig.7). Fig.8 shows the aspect 22
weeks after Zometa® was stopped. In
February 2011, an extraction of tooth
#35 was done and the clinical exam
revealed an extension of the osteonecrosis with a sub-total distal bone loss
especially on the right maxillary molars
quadrant (a large sequestrum was
meanwhile rejected) (Fig.9).
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Fig. 4: Sinus CT scan.

Fig. 5: Extensive bone curettage
up to the maxillary sinus.

Fig. 6: Bone loss at tooth #15.

Fig. 7: Bone loss at tooth #36 and #15.

Fig. 9a: Advanced mesial and distal bone
loss at the left posterior manbibule.

Fig. 8: 22 weeks after discontinuation.

Fig. 9b: Sub-total distal bone loss at the
right posterior maxilla.
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Fig. 10: Bilateral mandibular necrosis.

Fig. 11: Panoramic film showing bilateral
osteonecrosis with sequestrum.

other intervention on the necrotic bone
was considered.
During the follow-up he presented
respectively in March and May 2010
with left and right mandibular sequestrum (Fig.12). Note that in April 2010
the patient received 10 sessions of pelvic radiotherapy following a bilateral
acute back pain.

In November 2010 malodorous
purulent discharge appeared at the
site of the unhealed wound (Fig. 13).
Curettage of the inflammatory tissue
was then performed and the culture
of the pus revealed only normal oral
flora without other specific pathogens as Actinomyces. She was given
one month of amoxicillin and metronidazol with anti-bacterial oral rinse
(chlorhexidine). After a discussion
with the oncologist, he decided to suspend the treatment with iv Zometa®.
In December 2010, during her followup visit, the antibiotics were given for
another month and the patient was
seen again in January 2011: the mucosal healing was complete at the site of
tooth #48 and a 3mm thin sequestrum
was removed (Fig.14a,b). The plan was
then to extract lately tooth #26 while
having another month of antibiotics.
Finally, after four months of a non-stop
antibiotherapy (amoxicillin + metronidazol), the tooth #26 was removed on
April 1st, 2011 by a partial thickness
flap covering the wound with sutures

Fig. 12: Loss of left and right sequestrum.

Case 2
A 68-year old man presented in
January 2010 with acute and bilateral mandibular pain. The patient was
edentulous and wore a very old removable and complete dental prosthesis.
On physical exam, a bilateral mucosal ulceration was noted with halitosis accompanying an osteonecrosis
(Fig.10). The patient had a history of
multiple myeloma in February 2008
treated with chemotherapy. He also
received iv Zometa® (zoledronic acid)
one dose per month for a year (stopped
in April 2009). He also took blood thinners (Sintrom®) and lipid-lowering
(Simvast®).
The panoramic film done showed
a diffuse mandibular osteonecrosis
(Fig.11). Peripheral bone regularization
limited to the inflammatory gingiva
was thus performed and the patient
was given oral antibiotic (amoxicillin
+ clavulanate) and anti-bacterial oral
rinse (chlorhexidine). Apart from this
regularization to relieve the pain, no

Case 3
A 53-year old woman presented in
September 2010 with a healing defect at
the site of tooth #48 that was extracted
one year ago. She mentioned that a
bone sequestrum was spontaneously
eliminated in June 2010 while she was
taking Ibuprofen. A mucosal curettage
was then performed by her dentist. She
had a history of breast cancer in 2006
treated with Decapeptyl® and mastectomy. She was started on iv Zometa®
(zoledronic acid) in January 2009 followed by one dose every 6 months
(the next dose was programmed in
December 2010).
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Fig. 13: Infection of unhealed wound and
panoramic film.

Fig. 14b: Sequestrum

Fig. 14a: Healed wound.

Fig. 15: Surgical removing of the tooth
#26.

Fig. 16: Total mucosal healing of the area of
wisdom tooth #48.

Fig. 17: Osteonecrosis evolution from
October 28, 2010 to June 28, 2011.

Fig. 18: Removal of sequestrum from site
48 and complete mucosal healing on both
sites 48 and 26.

Fig. 19: Stabilization of the bone at the site of the missing tooth #48 and
incomplete alveolar healing three months after the extraction of tooth #26.
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and a dressing Coe-Pack®. Antibiotics
as well as antibacterial oral rinse
(chlorhexidine) were continued until
wound healing (Fig.15). The radiographic control of BRONJ in April 12th,
2011 at the site of tooth #48 showed
favorable bone remodeling consistent
with perfect healing of fibromucosa at
the clinical inspection (Fig.16). Fig.17
showed the evolution of osteonecrosis
on retroalveolar films between October
28th, 2010 and June 28th, 2011.
In juin11, a blood test, a lung X-ray
and an abdominal pelvic ultrasound
revealed no evidence for recurrence
or worsening of her cancer. Zometa
was finalized since the last injection in December that had not been
administered. Mucosal healing on
sites 48 and 26 was complete and a
small sequestrum that adheres to the
emergent fibromucosa was removed at
the forceps (Fig.18). Two retroalveolar
films were taken to sites 48 and 26. It
shows a stabilization of the bone at
48 and an incomplete alveolar healing
three months after the extraction of 26
(Fig.19).

Discussion
The three cases presented above
are similar concerning the development of jaw osteonecrosis in association with the intravenous route of
administration of BsP. However the
second case differs from the others in
that it was revealed few months after
the treatment was stopped. This is in
complete concordance with the case
definition of BRONJ [2] and with the
fact that more than 90% of the disease
is induced by iv bisphosphonates (Woo
et al., [3]). Moreover in the 3 cases,
BRONJ is not a spontaneous complication but was subsequent to trauma like
tooth extraction (cases 1 and 3) or the
presence of a denture (case 2). The low
risk of developing spontaneous BRONJ
is mentioned in many articles while
reviewing the literature [9, 10].
Advanced stages of BRONJ are presented in the cases above. A stage 3
disease is noted in case1 because of

evidence of sinus wall involvement. A
stage 2 disease concerns the cases 2
and 3 because of evidence of infection:
pain and ulceration in case 2 and pain
with pus in case 3 (Hoff et al., [11]).
The management of BRONJ in
all cases seems in concordance with
the recommendations of the AAOMS
presented in the position paper on
bisphosphonate-related osteonecrosis
of the Jaw—2009 update [4]. Note that
the first case was managed despite of
the poor knowledge available at that
time. Indeed a stage 2 BRONJ should
be treated with oral antibiotics, oral
antibacterial mouth rinse and superficial debridement to relieve tissue irritation. An extended surgical debridement
should be also considered for stage
3 with reconstruction by a plate or an
obturator periodically relined by a soft
material (Viscogel®, Dentsply-Detrey).
In addition, any bony sequestrum
should be removed without exposing
uninvolved bone and any symptomatic tooth at the site of the necrosis
should be extracted because it does
not exacerbate the process (Silverman
& Landesberg, [12]).
Concerning the management of
infection, any purulent discharge
should be sampled for culture. If there
is no evidence of actinomyces, oral
amoxicillin with or without metronidazole is sufficient to cover the germs
involved [4, 13]. Ruggiero [14] in 2006
recommended the biopsy only if a
metastasis is suspected and considered that hyperbaric oxygen therapy
is ineffective. The efficacy of this treatment is still controversial. Finally, the
discontinuation of iv BsP in patients
with BRONJ shows long-term benefits
in terms of stabilizing the necrotic site,
preventing new sites development and
reducing clinical symptoms. It should
be discussed with the oncologist to
study the balance between the risks
and benefits [4].
The duration and type of the antibiotics treatment is still controversial:
some authors support a long-term preoperative treatment with evidence of
better outcome: less recurrence and
better mucosal healing without evi-

dence of increased rate of actinomyces infection. Mitsimponas et al. [15]
administered ampicillin and clavulanate intravenously for 6 days followed
by an oral medication for at least 6 days.
Bagan et al. [16] recommended a 10-to15 day antibiotic regime with amoxicillin and clavulanate or clindamycin
accompanied by CHX mouth rinses.
For a poor response, they prolonged
this scheme for up to 1 month. Stanton
and Balasanian [17] administered only
antibiotics before operation if an active
inflammation was obvious. Otherwise
antibiotics were initiated immediately
after surgery [18].
Nowadays, prevention is the most
effective way to limit the development of BRONJ. First of all, the risk
of BRONJ is reduced if some precautions are taken before initiation the
treatment with BsP: oral evaluation
including panoramic x-ray, removal of
symptomatic teeth and complete all
the invasive dental procedures. This
procedure is possible if the systemic
condition of the patients permits the
treatment delay [4]. Moreover in an
asymptomatic patient taking iv BsP, frequent oral dental evaluation with strict
oral hygiene are crucial for reducing the
risk of BRONJ. Implants are not recommended and any elective jaw surgery
should be avoided or if necessary, BsP
discontinuation should be discussed
with the oncologist [4, 14].
Many studies have demonstrated
the potential for simvastatin to promote bone regeneration by enhancing osteblastic activity and inhibiting
osteoclastic activity: enhancing BMP
–induced osteoblast differentiation,
reversing the suppressive effect of TNF,
promoting phosphatase alkaline activity and mineralization, anti-inflammatory effect… It is also demonstrated
that low doses (1mg/kg/day orally)
decreases bone regeneration while
higher doses (20mg/kg/day orally)
stimulates it [19]. However other studies state that simvastin is similar to
placebo concerning the effect on bone
regeneration [20]. These contradicted
results are mainly due to the variability in the route of administration, the
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duration of exposure and the experimental animal model [19].
Finally, it is interesting to note in
connection with the case 3 the following elements:
-Osteonecrosis in the site 48 was
installed when the patient had
already undergone four injections
every six months.
-The suspension of the fifth injection and wound healing two
months later.
-The absence of another outbreak
of osteonecrosis despite the presence of residual roots at the site
of the tooth #26 which is in itself a
potential source of infection.
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